Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.
Study Type
OBSERVATIONAL
Enrollment
52
Samsung Medical Center
Seoul, South Korea
serum VEGF and Ang-2 level in lung inflammatory disease according to the presence of hemoptysis
We'll measure the serum VEFG and Ang-2 level of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Comparison of the serum VEGF and Ang-2 level (measured within a week from enrollment) according to the presence of hemoptysis will be primary outcome.
Time frame: up to 7 days after enrollment
to investigate association between angiogenesis factors and other factors such as inflammatory biomarker and hypoxia.
We'll measure the serum VEFG, Ang-2 level, and other factors such as inflammatory biomarkers and PaO2 of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Investigating association between angiogensis factors and other factors such as inflammatory biomarker and hypoxia, which were measured within a week from enrollment, will be secondary outcome.
Time frame: up to 7 days after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.